Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM)

1. Mora-Rodríguez, J.M.
2. Sánchez, B.G.
3. Bort, A.
4. Díaz-Yuste, A.
5. Ballester-González, R.
6. Arrieta, F.
7. Sebastián-Martín, A.
8. Díaz-Laviada, I.

Export

Export ×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export ×

This document cannot be exported because it belongs to another portal.

Full text

lock_opene_Buah handle

DOI: 10.1016/J.LFS.2023.122292 GOOGLE SCHOLAR HANDLE: https://hdl.handle.net/10017/60635

e_Buah Biblioteca Digital Universidad de Alcalá: lock_openOpen access Handle

Data source: Scopus